A Randomised, Double-Blind, Vehicle-Controlled Study of theSafety and Tolerability of BTX 1204 in Patients with Mild toModerate Atopic Dermatitis
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Cannabidiol (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Botanix Pharmaceuticals
- 19 Feb 2018 Planned End Date changed from 31 Jan 2018 to 30 Mar 2018.
- 19 Feb 2018 Status changed from not yet recruiting to recruiting.
- 13 Oct 2017 New trial record